VEEVA-SYSTEMS-INC.
Veeva Systems announced today at its European Commercial Summit the general availability of two new Veeva Commercial Cloud products: Veeva CRM Events Management and Veeva Align . These new offerings help life sciences companies to achieve sales and marketing goals more effectively, while keeping up with changing compliance requirements.
Veeva CRM Events Management allows companies to better manage all events in coordination with the field, and provides visibility into activities, speakers, attendees, and spend. Veeva Align is a global solution integrated with Veeva CRM for faster, more accurate sales territory alignments.
These products continue Veeva’s track record of delivering market-leading innovation and increasing value with each new release of Veeva CRM. They are also the latest addition to Veeva Commercial Cloud , a platform that brings together the rich data, compliant content, and interactions needed for life sciences companies to deliver a fully coordinated customer experience across multiple channels.
“Companies in the European life sciences market are under pressure to maintain their commercial performance while facing both economic and regulatory challenges. Veeva continues to deliver innovative products to give our customers a more effective way of doing business to meet these challenges,” said Jan van den Burg, vice president of commercial strategy at Veeva Europe. “By bringing together and leveraging deep but traditionally siloed sets of customer, market, and industry data, our customers can achieve high-quality, high-impact commercial outreach across multiple channels.”
NEW Veeva CRM Events Management
With many disconnected systems and diversity of approval workflows in use across event types and European territories, it is challenging to efficiently track speakers and spend. With the EFPIA’s June 2016 payment transparency reporting deadline now imminent, this is a major issue for companies in Europe. Matching the right speakers with the right audience is also difficult to coordinate across internal and external parties.
Veeva CRM Events Management helps companies plan and manage events more efficiently, compliantly, and in coordination with field and medical teams. It delivers a complete view of speakers, attendees, input into transfer of value reporting, and it integrates seamlessly with Veeva CRM for easier, more accurate attendee tracking. Built-in spend management also helps marketers ensure that funds are allocated to the right events while staying within budget.
NEW Veeva Align
Life sciences companies are deploying new commercial models, engaging with multiple stakeholders, and operating in an environment of constant change. This makes territory alignment critical yet challenging. The current approach is time and resource intensive, and omits key considerations such as rep skill level, customer channel preferences, and existing relationships. The result is inefficient use of resources, which impacts sales execution. With an estimated cost of €200–250 per rep call, it is vital that the right HCPs are being engaged.
Veeva Align delivers faster, more accurate alignments. With seamless integration with Veeva CRM, alignments are rapidly deployed for field feedback and collaboration. Even the largest territory assignments can be previewed in minutes rather than days. And, as a single global platform, Veeva Align provides centralized management, while still allowing local control.
In other news today, Veeva announced the global availability of Veeva KOL Data as a subscription , offering a single consolidated, global source of all key stakeholder information, and Veeva introduced Veeva Medical CRM to enable better KOL engagements.
Additional Information
For more on Veeva CRM Events Management, please visit: veeva.com/eu/eventsmgt
For more on Veeva Align, please visit: veeva.com/eu/align
Stay updated on the latest Veeva news on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 375 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit http://www.veeva.com/eu .
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the company’s filing on Form 10-Q for the period ended July 31, 2015. This is available on the company’s website at http://www.veeva.com/ under the Investors section and on the SEC’s website at http://www.sec.gov/ . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
###
View source version on businesswire.com: http://www.businesswire.com/news/home/20151202006542/en/
Contact:
For Veeva Systems Inc.
Sue Glanville
sue@catalystcomms.co.uk
+44
(0) 7715 817589
or
Cate Bonthuys
cate@catalystcomms.co.uk
+44
(0) 7746 546773
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom